Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer

被引:26
|
作者
Sun, Naihui [1 ]
Zhao, Xing [2 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Dept Pediat, Shenyang, Peoples R China
关键词
metabolic reprogramming; fatty acid; tumor microenvironment; prognosis; cancer; ACID-BINDING PROTEIN; POOR-PROGNOSIS; PPAR-GAMMA; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; FATTY; METASTASIS; CELLS; METABOLISM; EXPRESSION;
D O I
10.3389/fphar.2022.948610
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolic reprogramming is an emerging hallmark of tumor cells. In order to survive in nutrient-deprived environment, tumor cells rewire their metabolic phenotype to provide sufficient energy and build biomass to sustain their transformed state and promote malignant behaviors. Fatty acid uptake and trafficking is an essential part of lipid metabolism within tumor cells. Fatty acid-binding proteins (FABPs), which belongs to a family of intracellular lipid-binding protein, can bind hydrophobic ligands to regulate lipid trafficking and metabolism. In particular, adipocyte fatty acid binding protein (FABP4), one of the most abundant members, has been found to be upregulated in many malignant solid tumors, and correlated with poor prognosis. In multiple tumor types, FABP4 is critical for tumor proliferation, metastasis and drug resistance. More importantly, FABP4 is a crucial driver of malignancy not only by activating the oncogenic signaling pathways, but also rewiring the metabolic phenotypes of tumor cells to satisfy their enhanced energy demand for tumor development. Thus, FABP4 serves as a tumor-promoting molecule in most cancer types, and may be a promising therapeutic target for cancer treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Proteasome as an emerging therapeutic target in cancer
    Zavrski, I.
    Kleeberg, L.
    Kaiser, M.
    Fleissner, C.
    Heider, U.
    Sterz, J.
    Jakob, C.
    Sezer, O.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (05) : 471 - 485
  • [22] Ferroptosis: An emerging therapeutic target for oral cancer
    Balachander, Kannan
    Paramasivam, Arumugam
    ORAL ONCOLOGY, 2022, 131
  • [23] Autophagy in Cervical Cancer: An Emerging Therapeutic Target
    Pandey, Saumya
    Chandravati
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4867 - 4871
  • [24] Podoplanin: An emerging cancer biomarker and therapeutic target
    Krishnan, Harini
    Rayes, Julie
    Miyashita, Tomoyuki
    Ishii, Genichiro
    Retzbach, Edward P.
    Sheehan, Stephanie A.
    Takemoto, Ai
    Chang, Yao-Wen
    Yoneda, Kazue
    Asai, Jun
    Jensen, Lasse
    Chalise, Lushun
    Natsume, Atsushi
    Goldberg, Gary S.
    CANCER SCIENCE, 2018, 109 (05) : 1292 - 1299
  • [25] FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport
    Tian, Wenying
    Zhang, Wenjia
    Zhang, Yan
    Zhu, Tianyue
    Hua, Yuting
    Li, Hui
    Zhang, Qinglin
    Xia, Min
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [26] FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport
    Wenying Tian
    Wenjia Zhang
    Yan Zhang
    Tianyue Zhu
    Yuting Hua
    Hui Li
    Qinglin Zhang
    Min Xia
    Cancer Cell International, 20
  • [27] The emerging roles of HDACs and their therapeutic implications in cancer
    Hai, Rihan
    Yang, Deyi
    Zheng, Feifei
    Wang, Weiqin
    Han, Xing
    Bode, Ann M.
    Luo, Xiangjian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 931
  • [28] Fatty Acid Binding Protein 4 (FABP4) Plays an Important Role in Ovarian Cancer Metastasis
    Buell-Gutbrod, R.
    Dogan, S.
    Gwin, K.
    Lengvel, E.
    LABORATORY INVESTIGATION, 2010, 90 : 235A - 235A
  • [29] Fatty Acid Binding Protein 4 (FABP4) Plays an Important Role in Ovarian Cancer Metastasis
    Buell-Gutbrod, R.
    Dogan, S.
    Gwin, K.
    Lengyel, E.
    MODERN PATHOLOGY, 2010, 23 : 235A - 235A
  • [30] Arginase: An emerging and promising therapeutic target for cancer treatment
    Niu, Fanglin
    Yu, Yi
    Li, Zhuozhuo
    Ren, Yuanyuan
    Li, Zi
    Ye, Qiang
    Liu, Ping
    Ji, Chenshuang
    Qian, Lu
    Xiong, Yuyan
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 149